SciBase Holding AB (publ) (SCIB.ST)
SEK 0.37
(-6.03%)
SEK 0.37
(-6.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.27 Million SEK | -13.56% |
| 2022 | 24.61 Million SEK | 67.92% |
| 2021 | 14.66 Million SEK | 18.31% |
| 2020 | 12.39 Million SEK | -12.42% |
| 2019 | 14.14 Million SEK | 46.84% |
| 2018 | 9.63 Million SEK | -20.95% |
| 2017 | 12.18 Million SEK | 114.63% |
| 2016 | -83.3 Million SEK | 39.71% |
| 2015 | -138.16 Million SEK | -1641.01% |
| 2014 | 8.96 Million SEK | 19.58% |
| 2013 | 7.49 Million SEK | -84.23% |
| 2012 | 47.55 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 20.81 Million SEK | -1.56% |
| 2024 Q1 | 21.14 Million SEK | -0.65% |
| 2023 Q4 | 21.27 Million SEK | -7.78% |
| 2023 Q1 | 24.38 Million SEK | -0.94% |
| 2023 Q3 | 23.07 Million SEK | -10.57% |
| 2023 FY | 21.27 Million SEK | -13.56% |
| 2023 Q2 | 25.79 Million SEK | 5.79% |
| 2022 Q1 | 15.77 Million SEK | 7.58% |
| 2022 Q3 | 14.7 Million SEK | -2.27% |
| 2022 FY | 24.61 Million SEK | 67.92% |
| 2022 Q4 | 24.61 Million SEK | 67.41% |
| 2022 Q2 | 15.04 Million SEK | -4.59% |
| 2021 Q2 | 13.62 Million SEK | 38.37% |
| 2021 Q4 | 14.66 Million SEK | 13.99% |
| 2021 Q3 | 12.86 Million SEK | -5.64% |
| 2021 Q1 | 9.85 Million SEK | -20.51% |
| 2021 FY | 14.66 Million SEK | 18.31% |
| 2020 Q3 | 12.82 Million SEK | -13.69% |
| 2020 Q4 | 12.39 Million SEK | -3.4% |
| 2020 Q1 | 12.64 Million SEK | -10.63% |
| 2020 FY | 12.39 Million SEK | -12.42% |
| 2020 Q2 | 14.86 Million SEK | 17.54% |
| 2019 Q2 | 17.61 Million SEK | 5.56% |
| 2019 FY | 14.14 Million SEK | 46.84% |
| 2019 Q4 | 14.14 Million SEK | -6.99% |
| 2019 Q3 | 15.21 Million SEK | -13.63% |
| 2019 Q1 | 16.68 Million SEK | 73.16% |
| 2018 FY | 9.63 Million SEK | -20.95% |
| 2018 Q1 | 9.33 Million SEK | -23.4% |
| 2018 Q2 | 8.31 Million SEK | -10.91% |
| 2018 Q3 | 10.01 Million SEK | 20.46% |
| 2018 Q4 | 9.63 Million SEK | -3.83% |
| 2017 Q4 | 12.18 Million SEK | 33.42% |
| 2017 FY | 12.18 Million SEK | 114.63% |
| 2017 Q3 | 9.13 Million SEK | -10.5% |
| 2017 Q2 | 10.2 Million SEK | 23.12% |
| 2017 Q1 | 8.29 Million SEK | 109.95% |
| 2016 Q1 | 7.91 Million SEK | 105.73% |
| 2016 Q3 | 10.18 Million SEK | 7.51% |
| 2016 Q2 | 9.46 Million SEK | 19.62% |
| 2016 Q4 | -83.3 Million SEK | -918.31% |
| 2016 FY | -83.3 Million SEK | 39.71% |
| 2015 FY | -138.16 Million SEK | -1641.01% |
| 2015 Q2 | 15.66 Million SEK | 80.1% |
| 2015 Q3 | 9.69 Million SEK | -38.1% |
| 2015 Q4 | -138.16 Million SEK | -1524.84% |
| 2015 Q1 | 8.69 Million SEK | 7.25% |
| 2014 FY | 8.96 Million SEK | 19.58% |
| 2014 Q4 | 8.1 Million SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | 7.49 Million SEK | -84.23% |
| 2012 FY | 47.55 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -93.472% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.204% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.204% |
| Arcoma AB | 33.3 Million SEK | 36.112% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 93.546% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.348% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 92.398% |
| CellaVision AB (publ) | 212.32 Million SEK | 89.978% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -49.877% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -209.771% |
| C-Rad AB (publ) | 122.4 Million SEK | 82.616% |
| Duearity AB (publ) | 17.53 Million SEK | -21.38% |
| Dignitana AB (publ) | 37.56 Million SEK | 43.36% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -7.465% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.914% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -3.29% |
| Iconovo AB (publ) | 14.55 Million SEK | -46.201% |
| Integrum AB (publ) | 22.07 Million SEK | 3.601% |
| Luxbright AB (publ) | 7 Million SEK | -203.966% |
| Mentice AB (publ) | 163.55 Million SEK | 86.99% |
| OssDsign AB (publ) | 105.25 Million SEK | 79.785% |
| Paxman AB (publ) | 44.5 Million SEK | 52.194% |
| Promimic AB (publ) | 16.15 Million SEK | -31.703% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 65.774% |
| ScandiDos AB (publ) | 37.18 Million SEK | 42.78% |
| Sectra AB (publ) | 1.64 Billion SEK | 98.704% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 51.709% |
| Senzime AB (publ) | 58.06 Million SEK | 63.355% |
| SpectraCure AB (publ) | 14.97 Million SEK | -42.09% |
| Stille AB | 172.64 Million SEK | 87.675% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.42% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 91.508% |